[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Zhiyong Huang\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":108},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,65,86],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100537629","impact-of-splenectomy-on-the-efficacy-of-targeted-therapy-and-immunotherapy-in-unresectable-hcc-patients-with-cirrhotic-portal-hypertension-100537629",false,"NCT06280313","Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension","Inclusion Criteria:\n\n1. Patients aged 18 to 75 years (inclusive).\n2. No prior systemic antitumor treatment or meeting the criteria for splenectomy during treatment.\n3. Clinical or pathological diagnosis of hepatocellular carcinoma (HCC) that is unresectable initially or has recurred after surgery.\n4. HBV-DNA less than 1\\*10\\^5 copies\u002Fml and undergoing antiviral therapy.\n5. ECOG performance status score of 0-1, without significant organ dysfunction.\n6. Child-Pugh score of 5-7.\n7. Spleen thickness \\>4.0 cm.\n8. History of esophagogastric varices, red signs, or variceal bleeding with or without splenomegaly.\n9. Splenomegaly with WBC \\\u003C2.5 × 10\\^9\u002FL and PLT \\\u003C70 × 10\\^9\u002FL, or splenomegaly with WBC \\\u003C2.0 × 10\\^9\u002FL or PLT \\\u003C50 × 10\\^9\u002FL.\n10. Important organ functions meeting the following criteria: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3\\*ULN, total bilirubin ≤ 3\\*ULN; International normalized ratio (INR) ≤ 1.5\\*ULN; prothrombin time ≤ 1.5\\*ULN; creatinine ≤ 1.5\\*ULN.\n11. Able to undergo local treatments such as transarterial chemoembolization (TACE), hepatic artery infusion chemotherapy (HAIC), selective internal radiation therapy with yttrium-90 (SIRT), stereotactic body radiation therapy (SBRT), and ablation (including radiofrequency ablation (RFA) and microwave ablation (MWA)).\n12. Willing to provide informed consent.\n13. Expected survival time of more than 3 months.\n\nExclusion Criteria:\n\n1. History of or concurrent active malignancy (excluding malignancies that have been cured for over 5 years or in situ cancers that can be completely cured with adequate treatment).\n2. Presence of central nervous system metastasis or a history of brain metastasis.\n3. History of organ transplantation.\n4. History of surgery in the head, chest, or abdomen within the past six months.\n5. Child-Pugh class C liver function or significant ascites.\n6. Marked thrombosis in the portal venous system or extensive cancer thrombus in the main portal vein.\n7. Activated partial thromboplastin time (APTT) or prothrombin time (PT) exceeding 1.5 times the upper limit of normal (as per the normal values of the clinical trial research center), or evidence of bleeding tendency or history of bleeding within the two months prior to enrollment, regardless of severity.\n8. Ongoing active infection within 7 days after completion of systemic antibiotic therapy.\n9. Active coronary artery disease, severe\u002Funstable angina, or newly diagnosed angina or myocardial infarction within the past 12 months before enrollment.\n10. Thrombotic or embolic events within the past 12 months, such as cerebrovascular accidents (including transient ischemic attacks), pulmonary embolism, or deep vein thrombosis.\n11. New York Heart Association (NYHA) class II or above congestive heart failure.\n12. Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), positive syphilis serology, untreated active hepatitis (defined as HBV-DNA ≥ 10\\^5 copies\u002Fml; HCV-RNA higher than the lower limit of detection for the assay).\n13. Any active, known, or suspected autoimmune disease. Stable subjects not requiring systemic immunosuppressive therapy may be included, such as those with type 1 diabetes, hypothyroidism requiring only hormone replacement therapy, and skin diseases not requiring systemic treatment (e.g., vitiligo, psoriasis, and alopecia).\n14. Interstitial lung disease, non-infectious pneumonia, or uncontrolled systemic diseases (e.g., diabetes, hypertension, pulmonary fibrosis, and acute pneumonia).\n15. Pregnant or lactating women or females with a positive pregnancy test prior to the first dose who have the potential for pregnancy.\n16. The investigator deems the subject inappropriate for participation in this clinical study due to any clinical or laboratory abnormalities or compliance issues.\n17. Severe psychological or mental abnormalities.\n18. Participation in another drug clinical trial within the past 4 weeks.\n19. Other reasons that the investigator considers unsuitable for enrollment.","ALL","18 Years","75 Years",{"count":19,"type":20},60,"ESTIMATED","OBSERVATIONAL","Currently, the combination of targeted therapy and immunotherapy is the first-line treatment for advanced hepatocellular carcinoma (HCC). However, a subset of HCC patients with severe splenomegaly, splenic hyperfunction, and esophagogastric varices due to liver cirrhosis and portal hypertension may be unable to undergo or sustain the combination therapy, ultimately missing the optimal treatment window. Prior studies have indicated that splenectomy can significantly improve liver function and hepatic reserve in cirrhotic patients. It also addresses splenic hyperfunction and reduces the risk of bleeding from esophagogastric varices by combining splenectomy with devascularization around the cardia. Additionally, splenectomy contributes to the improvement of liver fibrosis and restoration of immune function in cirrhotic patients. This study aims to elucidate the impact of splenectomy on the efficacy of combination targeted and immunotherapy in unresectable HCC patients with cirrhotic portal hypertension, particularly those with poor liver function, significant splenic hyperfunction, and severe esophagogastric varices. The research also seeks to explore whether changes in the tumor immune microenvironment before and after splenectomy can influence the effectiveness of immunotherapy. Ultimately, the goal is to provide therapeutic opportunities for this specific patient population.",[24],"Unresectable Hepatocellular Carcinoma",[26,27,28,29],"Immunotherapy","Targeted therapy","Splenectomy","HCC","RECRUITING","2025-08-14",{"date":33,"type":34},"2025-08-15","ACTUAL",{"date":36,"type":34},"2024-03-15",{"date":38,"type":20},"2028-03-15",{"name":40,"class":41},"Zhiyong Huang","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":42},"100522567","phase-1-immunotherapy-using-tumor-infiltrating-lymphocytes-for-patients-with-advanced-liver-cancer-100522567","NCT06084299","Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Advanced Liver Cancer","Inclusion Criteria:\n\n* The subjects must be informed of the study before the test and voluntarily sign a written informed consent.\n* Age of the patients was between 18\\~70 years\n* Eligible patients have histologically proven advanced liver cancer\n* Eastern Cooperative Oncology Group (ECOG) performance status was 0-1\n* Metastatic lesions are confirmed by PET-CT, CT, MR and\u002For intraoperative exploration (more than 3, at least one accessible metastasis to procure for TILs)\n* Patients have at least one separate additional measurable tumour lesion according to RECIST version 1.1 standard.\n* The disease has progressed after at least two previous lines of standard treatment and there is no effective treatment option available\n* Adequate normal organ and marrow function were present, including absolute neutrophil count ≥ 1×10\\^9\u002FL, leukocyte count ≥ 3×10\\^9\u002FL, platelet count ≥ 75×10\\^9\u002FL, hemoglobin ≥ 80 g\u002FL, AST and ALT ≤ 2× of upper limit of normal, Serum creatinine ≤ 1.5× upper normal limits, Serum total bilirubin ≤ 1.5× upper normal limits\n* Female subjects of childbearing age must have a negative urine or serum HCG test within 7 days before cell reinfusion\n* Provide at least one gram of fresh tumor tissue and 10ml of peripheral blood for whole exome sequencing and TIL isolation and culture.\n* Expected survival was at least 3 months\n* Child-Push liver function score grade is A within seven days before the cell reinfusion.\n\nExclusion Criteria:\n\n* With previous or concurrent other active cancer (except carcinoma in situ that has been cured without onset within 5 years, or those that can be cured by adequate treatment)\n* Patients with metastasis to Central Nervous System or brain\n* Have received organ transplantation in the past\n* Received major liver surgery within 4 weeks before the first administration (except liver metastases biopsy).\n* Received local treatment of the liver or other parts within 4 weeks before the first administration (transcatheter arterial chemoembolization \\[TACE\\], transcatheter arterial embolization \\[TAE\\], hepatic artery infusion \\[HAI\\], radiotherapy, radioembolization or ablation). Subjects are not eligible to participate in the study if the above-mentioned treatment is carried out between the last dose of sorafenib or oxaliplatin-containing regimen and the first study administration.\n* After CT angiography examination, there is severe arterial embolism or hepatic artery vascular variation.\n* APTT or PT \\>= 5 UNL, or with bleeding evidence in two months or bleeding history in prior to the clinical study, no matter how serious it is\n* Active inflammation within 7 days after systemic antibiotics treatment\n* Subjects who have undergone major surgery or severe trauma such as laparotomy, thoracotomy, and laparoscopic organ removal within 4 weeks before enrollment.\n* Active coronary artery disease, serious or unstable angina pectoris, or newly diagnosed angina pectoris or myocardial infarction within 12 months prior to the clinical study\n* Thrombosis or embolism event within 12 months prior to the clinical study, such as cerebrovascular accident ( including TIA) or pulmonary embolism\n* Congestive heart failure of NYHA \\>= Class II\n* Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), untreated active hepatitis (hepatitis B, defined as HBV-DNA ≥ 500 IU\u002Fml C Hepatitis, defined as HCV-RNA higher than the detection limit of the analytical method) or co-infection with hepatitis B and hepatitis C.\n* Presence of any active, known or suspected autoimmune disease. Subjects in a stable state who do not require systemic immunosuppressive therapy are allowed, such as: type 1 diabetes mellitus, hypothyroidism requiring only hormone replacement therapy, and skin diseases that do not require systemic therapy (e.g., vitiligo, psoriasis disease and hair loss).\n* Any interstitial lung disease, noninfectious causes of lung inflammation, or uncontrolled systemic disease (e.g. diabetes, pulmonary fibrosis, or acute pneumonia)\n* Any adverse event of CTCAE (Ver 5.0) grade 2 or higher induced by previous treatment, except anemia, hair loss, and skin pigmentation\n* Pregnant or lactating women or those who are positive in pregnancy test before 1st injection\n* The investigator believes that the subject has any clinical or laboratory abnormalities or compliance problems and is not suitable for participating in this clinical study.\n* With serious psychological or mental abnormalities\n* Joined other clinical trials in four weeks prior to this study\n* Patients who have a history of hypersensitivity to cyclophosphamide and fludarabine.\n* Other researchers think that they are not suitable for enrollment.","70 Years",{"count":51,"type":20},16,"INTERVENTIONAL",[54],"PHASE1","Single-arm, open-label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocytes (TIL) infusion followed by IL-2 after a non-myeloablative(NMA) lymphodepletion preparative regimen for the treatment of patients with advanced liver cancer.",[57],"Liver Cancer",{"date":59,"type":34},"2025-08-19",{"date":61,"type":34},"2020-05-27",{"date":63,"type":20},"2026-08-30",{"name":40,"class":41},{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":72,"targetDuration":4,"studyType":52,"phases":73,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":42},"100584979","phase-1-icaritin-soft-capsulestaceimmunotherapytargeted-therapy-versus-taceimmunotherapytargeted-therapy-for-unresectable-hepatocellular-carcinoma-100584979","NCT06896396","Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma","Icaritin Soft Capsules and TACE Combined with Immunotherapy and Targeted Therapy Versus TACE Combined with Immunotherapy and Targeted Therapy for Unresectable Hepatocellular Carcinoma：a Prospective, Double-arm, Exploratory Study","Inclusion Criteria:\n\n* 1\\) Age range: 18-75 years old; 2) Patients diagnosed with hepatocellular carcinoma or cirrhosis through histology\u002Fcytology meet the clinical diagnostic criteria for hepatocellular carcinoma by the American Association for the Study of the Liver (AASLD). The clinical diagnostic criteria refer to the \"Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2024 Edition)\"; 3) Advanced primary liver cancer patients who have not received systematic treatment in the past or advanced liver cancer patients who have not received systematic treatment and have relapsed after radical resection; 4) Diseases are not suitable for radical surgery, transplantation, or ablation, but diseases are suitable for TACE treatment 5) At least one measurable lesion. Single tumor, diameter ≤ 10.0cm or multiple tumors; Number ≤ 10; The tumor burden of the lesion is less than 50%; 6) ECOG score 0-1 points; 7) Child Pugh liver function grade A; 8) Expected lifespan ≥ 3 months; 9) Blood, liver, and kidney function meet the following criteria:\n\n  1. Absolute neutrophil count ≥ 1.0 × 109\u002FL;\n  2. Platelet count ≥ 75 × 109\u002FL;\n  3. Hemoglobin concentration ≥ 90g\u002FL;\n  4. Serum albumin concentration ≥ 28g\u002FL;\n  5. Serum total bilirubin ≤ 3 x upper limit of normal (ULN);\n  6. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 × ULN;\n  7. The prothrombin time extension shall not exceed ULN6s;\n  8. Creatinine\\\u003C1.5 × ULN or creatinine clearance rate (CrCl)\\>60 mL\u002Fmin (Cockcroft Gault formula); 10) If the patient is HBsAg positive, HBV-DNA should be below 2000 IU\u002Fml (10000 copies\u002Fml) during treatment; 11) Women with fertility must undergo a negative pregnancy test; 12) Acceptable contraceptive methods must be used during the research period; 13) Can understand and be willing to sign a written informed consent form; 14) Capable of swallowing and absorbing oral pills; 15) Use up to 3 types of antihypertensive drugs to fully control blood pressure, defined as systolic\u002Fdiastolic blood pressure ≤ 150\u002F90 mmHg during screening, and no change in antihypertensive treatment within the first week\u002Fweek prior to the first cycle.\n\nExclusion Criteria:\n\n* 1\\) Diffuse infiltrative lesions of the liver and brain metastases; 2) There are TACE contraindications, such as portosystemic shunt, hepatic blood flow and obvious atherosclerosis; 3) Individuals allergic to intravenous contrast agents; 4) Local treatment has been performed on existing lesions (e.g.: TACE、 Melting, particles TARE、 Hepatic artery infusion chemotherapy or radiotherapy); 5) The subject is unable to undergo enhanced liver CT or MRI scans; 6) Previous history of liver transplantation or current candidate for liver transplantation; 7) Pregnant, lactating women or participants planning to undergo contraceptive procedures within 2 years; 8) Patients with combined HIV and syphilis infections; 9) Patients with other concurrent malignant tumors or other malignant tumors within the first 5 years of enrollment; 10) Patients with severe functional impairments of the heart, kidneys, and other organs; 11) Severe clinical active infection\\>Level 2 (NCI-CTC version 5.0); 12) Mental illness patients who may affect the informed consent process; The patient is unable to take oral medication; The patient participated in clinical trials of other drugs within 12 months prior to enrollment.\n\n  13\\) Patients who have experienced esophageal or gastric variceal rupture bleeding within the past 3 months, or have unconfirmed severe varices and are at high risk; 14) Has bleeding or thrombotic disease or is undergoing thrombolytic therapy; 15) Clinical significant hemoptysis or tumor bleeding for any reason within 2 weeks prior to the first administration of the study intervention; 16) Major cardiovascular damage within the 12 months prior to the first administration of the investigational drug, such as a history of NYHA class II or higher congestive heart failure, unstable angina, myocardial infarction or cerebrovascular accident stroke, or arrhythmia related to hemodynamic instability; 17) There is clinically significant ascites during physical examination, which cannot be controlled with medication; 18) History of autoimmune diseases or immunodeficiency, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener's granulomatosis, Sjogren's syndrome, Guillain Barr é syndrome, or multiple sclerosis 19) Idiopathic pulmonary fibrosis, organizing pneumonia (such as bronchiolitis obliterans), drug-induced pneumonia, or history of idiopathic pneumonia, or evidence of active pneumonia on chest CT scan during screening 20) Known to be allergic to any component of the investigational drug formulation; 21) Other situations where the researcher deems it inappropriate to participate in the study.",{"count":19,"type":20},[54,74],"PHASE2","Hepatocellular carcinoma (HCC) is one of the most common malignant tumors and the leading cause of cancer-related death worldwide. Surgical resection has always been the best hope for long-term survival of patients with HCC. However, only a few patients have the opportunity to undergo surgery, and more than 70% of HCC patients have lost the opportunity of surgery at the time of diagnosis. The treatment measures for these patients are mainly transcatheter arterial chemoembolization and systemic therapy. In recent years, systemic therapies represented by targeted therapy and immunotherapy have made important progress in the field of liver cancer, improving the survival of patients with advanced unresectable HCC. Icaritin soft capsule is a monomer compound extracted, isolated, purified and enzymatically hydrolyzed from the natural medicinal plant Epimedium. It was approved for marketing on January 10, 2022 for patients with advanced first-line HCC. Icaritin soft capsules have the potential to delay TKI resistance and enhance the efficacy of PD-1 inhibitors. The aim of this study is to explore whetherIcaritin soft capsules and TACE combined with Immunotherapy and Targeted Therapy can improve the therapeutic effect of advanced HCC, ultimately prolong the survival time of patients, and provide a new treatment direction for patients with advanced HCC.",[24],"NOT_YET_RECRUITING","2025-03-20",{"date":80,"type":34},"2025-03-26",{"date":82,"type":20},"2025-04-01",{"date":84,"type":20},"2028-02-01",{"name":40,"class":41},{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":92,"targetDuration":4,"studyType":52,"phases":94,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":42},"100552220","phase-1-palliative-hepatectomy-combined-with-targeted-therapy-and-immunotherapy-for-advanced-hepatocellular-carcinoma-100552220","NCT06470256","Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma","Inclusion Criteria:\n\n1. Patients aged 18 to 75 years (inclusive).\n2. No prior systemic antitumor treatment or surgical treatment.\n3. Clinical or pathological diagnosis of hepatocellular carcinoma (HCC).\n4. The primary liver lesion is mainly isolated liver tumors, with a tumor burden exceeding 90% of the total tumor burden, and technically capable of complete resection. Simultaneously merging ① intrahepatic metastasis: the number of metastatic tumors is ≥ 3 and the sum of tumor diameters is ≤ 3cm; Or ② Extrahepatic metastasis: Extrahepatic metastasis does not exceed one organ, metastatic tumors do not exceed three, and the total diameter does not exceed 3cm. Or ③ if combined with portal vein tumor thrombus or hepatic vein tumor thrombus, it can be removed or completely removed together with the main tumor, and the tumor thrombus does not enter the superior mesenteric vein or inferior vena cava.\n5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1, without significant organ dysfunction.\n6. Child-Pugh class A.\n7. HBV-DNA less than 1\\*10\\^5 copies\u002Fml and undergoing antiviral therapy.\n8. Important organ functions meeting the following criteria: White Blood Cell (WBC) ≥2.5 × 10\\^9\u002FL ;Platelet (PLT) ≥75 × 10\\^9\u002FL;Hemoglobin (HB) ≥ 9g\u002FdL;Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ≤ 3\\*ULN, Total Bilirubin ≤ 3\\*ULN; International Normalized Ratio (INR) ≤ 1.5\\*ULN; Prothrombin Time ≤ 1.5\\*ULN; Creatinine ≤ 1.5\\*ULN.\n9. Expected survival time of more than 3 months.\n10. According to the RECIST v1.1 standard, postoperative patients with at least one longest diameter of 1 cm or more measurable tumors.\n11. Willing to provide informed consent.\n\nExclusion Criteria:\n\n1. History of or concurrent active malignancy (excluding malignancies that have been cured for over 5 years or in situ cancers that can be completely cured with adequate treatment).\n2. Presence of central nervous system metastasis or a history of brain metastasis.\n3. History of organ transplantation.\n4. History of surgery in the head, chest, or abdomen within the past six months.\n5. Child-Pugh class C liver function or massive ascites.\n6. Ongoing active infection within 7 days after completion of systemic antibiotic therapy.\n7. Active coronary artery disease, severe\u002Funstable angina, or newly diagnosed angina or myocardial infarction within the past 12 months before enrollment.\n8. Thrombotic or embolic events within the past 12 months, such as cerebrovascular accidents (including transient ischemic attacks), pulmonary embolism, or deep vein thrombosis.\n9. New York Heart Association (NYHA) class II or above congestive heart failure.\n10. Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), positive syphilis serology, untreated active hepatitis (defined as HBV-DNA ≥ 10\\^5 copies\u002Fml; HCV-RNA higher than the lower limit of detection for the assay).\n11. Any active, known, or suspected autoimmune disease. Stable subjects not requiring systemic immunosuppressive therapy may be included, such as those with type 1 diabetes, hypothyroidism requiring only hormone replacement therapy, and skin diseases not requiring systemic treatment (e.g., vitiligo, psoriasis, and alopecia).\n12. Interstitial lung disease, non-infectious pneumonia, or uncontrolled systemic diseases (e.g., diabetes, hypertension, pulmonary fibrosis, and acute pneumonia).\n13. Pregnant or lactating women or females with a positive pregnancy test prior to the first dose who have the potential for pregnancy.\n14. The investigator deems the subject inappropriate for participation in this clinical study due to any clinical or laboratory abnormalities or compliance issues.\n15. Severe psychological or mental abnormalities.\n16. Participation in another drug clinical trial within the past 4 weeks.\n17. Other reasons that the investigator considers unsuitable for enrollment.",{"count":93,"type":20},50,[54],"Hepatocellular carcinoma (HCC) is one of the most common malignant tumors and the leading cause of cancer-related death worldwide. Surgical resection has always been the best hope for long-term survival of patients with HCC. However, due to the fact that most patients are already in the middle and late stages of treatment, only about 20% of patients have the opportunity to undergo surgical resection. Palliative cytoreductive surgery has been used in the treatment of a variety of malignant tumors, but it is not recommended for the treatment of HCC. Under the premise of targeted therapy and immunotherapy, palliative hepatectomy can reduce tumor burden and may further improve the therapeutic effect of HCC. The aim of this study is to explore whether palliative hepatectomy combined with targeted therapy and immunotherapy can improve the therapeutic effect of advanced HCC, ultimately prolong the survival time of patients, and provide a new treatment direction for patients with advanced HCC.",[97],"Advanced Hepatocellular Carcinoma",[29,99,26,27],"Palliative Hepatectomy","2024-06-17",{"date":102,"type":34},"2024-06-24",{"date":104,"type":34},"2024-06-01",{"date":106,"type":20},"2028-06-01",{"name":40,"class":41},""]